ASCO 2023: highlights in non-small cell lung cancer

3 Views

07/04/23

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, gives an overview of influential lung cancer trials at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including overall survival findings from the Phase III ADAURA trial (NCT02511106), which ****essed osimertinib in non-small cell lung cancer (NSCLC) in the adjuvant setting. Dr Sabari additionally highlights results from the ALINA trial (NCT03456076) of alectinib in NSCLC. This interview took place at ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.